On subclasses of opioid analgesics

References

• Raffa RB, Beckett JR, Brahmbhatt VN, et al. Orally active opioid compounds from a non-poppy source. J Med Chem 2013;56:4840-8
   PubMed Web of Science ®Google Scholar
• Meldrum M. The ladder and the clock: cancer pain and public policy at the end of the twentieth century. J Pain Symptom Manage 2005;29:41-54
   PubMed Web of Science ®Google Scholar
• Bennett DS, Carr DB. Opiophobia as a barrier to the treatment of pain. J Pain Palliat Care Pharmacother 2002;16:105-9
   PubMed Web of Science ®Google Scholar
• Weissman DE, Gordon D, Bidar-Sielaff S. Cultural aspects of pain management. J Palliat Med 2004;7:715-16
   PubMedGoogle Scholar
• Thota RS, Jain P, Bakshi SG, Dhanve CN. Opioid-prescribing practices in chronic cancer pain in a tertiary care pain clinic. Indian J Palliat Care 2011;17:222-6
   PubMedGoogle Scholar
• Paice JA, Toy C, Shott S. Barriers to cancer pain relief: fear of tolerance and addiction. J Pain Symptom Manage 1998;16:1-9
   PubMed Web of Science ®Google Scholar
• Davis MP, Walsh D. Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Care 2004;21:137-42
   PubMedGoogle Scholar
• Ziegler SJ, Lovrich NP Jr. Pain relief, prescription drugs, and prosecution: a four-state survey of chief prosecutors. J Law Med Ethics 2003;31:75-100
   PubMed Web of Science ®Google Scholar
• Mercadante S, Fulfaro F. World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol 2005;16(Suppl 4):iv132-5
   PubMed Web of Science ®Google Scholar
• Bonica JJ. History of pain concepts and pain therapy. Mt Sinai J Med 1991;58:191-202
   PubMed Web of Science ®Google Scholar
• Raffa RB. Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther 2001;26:257-64
   PubMed Web of Science ®Google Scholar
• Raffa RB, Clark-Vetri R, Tallarida RJ, Wertheimer AI. Combination strategies for pain management. Expert Opin Pharmacother 2003;4:1697-708
   PubMed Web of Science ®Google Scholar
• Pergolizzi J. Chronic pain – moving from symptom control to mechanism-based treatment. Curr Med Res Opin 2011;27:2079-80
   PubMed Web of Science ®Google Scholar
• Snyder SH, Pasternak GW. Historical review: opioid receptors. Trends Pharmacol Sci 2003;24:198-205
   PubMed Web of Science ®Google Scholar
• Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355-474
   PubMed Web of Science ®Google Scholar
• Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest 2010;120:3779-87
   PubMed Web of Science ®Google Scholar
• Mercer SL, Coop A. Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance. Curr Top Med Chem 2011;11:1157-64
   PubMed Web of Science ®Google Scholar
• Xue JC, Chen C, Zhu J, et al. Differential binding domains of peptide and non-peptide ligands in the cloned rat kappa opioid receptor. J Biol Chem 1994;269:30195-9
   PubMed Web of Science ®Google Scholar
• Raffa RB, Martinez RP, Connelly CD. G-protein antisense oligodeoxyribonucleotides and mu-opioid supraspinal antinociception. Eur J Pharmacol 1994;258:R5-7
   PubMed Web of Science ®Google Scholar
• Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 2013;12:205-16
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Olson ER, Cassidy MP, et al. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 2007;323:346-55
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, Higgins JW. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. Drug Metab Dispos 2012;40:1825-33
   PubMed Web of Science ®Google Scholar
• Volpe DA, McMahon Tobin GA, Mellon RD, et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 2011;59:385-90
   PubMed Web of Science ®Google Scholar
• Okura T, Hattori A, Takano Y, et al. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos 2008;36:2005-13
   PubMed Web of Science ®Google Scholar
• Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006;79:461-79
   PubMed Web of Science ®Google Scholar
• Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001;297:688-95
   PubMed Web of Science ®Google Scholar
• Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2004;2:395-402
   PubMedGoogle Scholar
• Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003;28:2000-9
   PubMed Web of Science ®Google Scholar
• Cowan A. Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl 2003;133:3-8, discussion 23-4
   Google Scholar
• Budd K, Raffa RB (eds). Buprenorphine – The Unique Opioid Analgesic. Stuttgart–New York: Thieme, 2005
   Google Scholar
• Christoph T, Kogel B, Schiene K, et al. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 2005;507:87-98
   PubMed Web of Science ®Google Scholar
• Raffa RB, Ding Z. Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist. Acute Pain 2007;9:145-52
   Google Scholar
• Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:627-32
   PubMed Web of Science ®Google Scholar
• Wheeler-Aceto H, Cowan A. Buprenorphine and morphine cause antinociception by different transduction mechanisms. Eur J Pharmacol 1991;195:411-13
   PubMed Web of Science ®Google Scholar
• Ding Z, Raffa RB. Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol 2009;157:831-43
   PubMed Web of Science ®Google Scholar
• Tallarida RJ, Cowan A, Raffa RB. On deriving the dose–effect relation of an unknown second component: an example using buprenorphine preclinical data. Drug Alcohol Depend 2010;109:126-9
   PubMed Web of Science ®Google Scholar
• Raffa RB, Friderichs E. The basic science aspect of tramadol hydrochloride. Pain Reviews 1996;3:249-71
   Google Scholar
• Nakajima K, Obata H, Iriuchijima N, Saito S. An increase in spinal cord noradrenaline is a major contributor to the antihyperalgesic effect of antidepressants after peripheral nerve injury in the rat. Pain 2012;153:990-7
   PubMed Web of Science ®Google Scholar
• Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995;332:1685-90
   PubMed Web of Science ®Google Scholar
• Bianchi M, Broggini M, Balzarini P, et al. Effects of tramadol on synovial fluid concentrations of substance P and interleukin-6 in patients with knee osteoarthritis: comparison with paracetamol. Int Immunopharmacol 2003;3:1901-8
   PubMed Web of Science ®Google Scholar
• Raffa RB, Friderichs E, Reimann W, et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993;267:331-40
   PubMed Web of Science ®Google Scholar
• Stoops WW, Lofwall MR, Nuzzo PA, et al. Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment. Psychopharmacology (Berl) 2012;223:427-38
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kogel B, et al. (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-76
   PubMed Web of Science ®Google Scholar
• Gillen C, Haurand M, Kobelt DJ, Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol 2000;362:116-21
   PubMed Web of Science ®Google Scholar
• Schröder W, Vry JD, Tzschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010;14:814-21
   PubMed Web of Science ®Google Scholar
• Schröder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 2011;337:312-20
   PubMed Web of Science ®Google Scholar
• Cowan A, Raffa RB, Tallarida CS, et al. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit. Eur J Pain 2014. Epub ahead of print. DOI 10.1002/j.1532-2149.2014.00461.x
   Google Scholar
• Hartrick C, Van Hove I, Stegmann JU, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009;31:260-71
   PubMed Web of Science ®Google Scholar
• Daniels S, Casson E, Stegmann JU, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin 2009;25:1551-61
   PubMed Web of Science ®Google Scholar
• Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010;30:489-505
   PubMed Web of Science ®Google Scholar
• Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 2010;14:781-3
   PubMed Web of Science ®Google Scholar
• Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004;9:641-51
   PubMed Web of Science ®Google Scholar
• Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007;12:34-42
   PubMed Web of Science ®Google Scholar
• Linz K, Christoph T, Tzschentke TM, et al. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. J Pharmacol Exp Ther 2014;349:535-48
   PubMed Web of Science ®Google Scholar
• Poras H, Bonnard E, Dange E, et al. New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment. J Med Chem 2014;57:5748-63
   PubMed Web of Science ®Google Scholar